Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study.
Study Goal
The researchers aimed to assess the effect of a gluten-free diet (GFD) on patients with lymphocytic enteritis (LE) who also had irritable bowel syndrome (IBS) and fibromyalgia syndrome (FMS).
Results Summary
The GFD led to slight but significant improvements in symptoms (26-29% reduction in tender points, FIQ, HAQ, and VAS scores, and a 27% increase in SF-36 scores) in the LE (Marsh stage 1) group, but had almost no effect in the IBS plus FMS/Marsh stage 0 group.
Population
97 adult females with IBS and FMS, of whom 58 had LE (Marsh stage 1) and 39 had normal duodenal biopsies (Marsh stage 0).
Effective Dosage
Not specified
Duration
1 year
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | increase | all outcome measures | Marsh stage 1 group (IBS plus FMS adult females with lymphocytic enteritis) | - | somewhat better | #1 |
gluten-free diet (GFD) | decrease | TPs, FIQ, HAQ and VAS scales | Marsh stage 1 group (IBS plus FMS adult females with lymphocytic enteritis) | 26 to 29% | mean decrease | #2 |
gluten-free diet (GFD) | increase | SF-36 physical and mental component scores | Marsh stage 1 group (IBS plus FMS adult females with lymphocytic enteritis) | 27% | increase | #3 |
gluten-free diet (GFD) | no change | - | IBS plus FMS/Marsh stage 0 group (IBS plus FMS adult females with normal duodenal biopsy) | - | almost no effect | #4 |
gluten-free diet (GFD) | increase | all symptoms | LE-related IBS/FMS subgroup of patients | - | slight but significant improvement | #5 |
INTRODUCTION: Irritable bowel syndrome (IBS), lymphocytic enteritis (LE) and fibromyalgia syndrome (FMS) are three common disorders. Since a gluten-free diet (GFD) has been shown to be helpful in LE, we aimed to assess its effect in a series of LE patients also diagnosed with IBS and FMS. METHODS: The study sample comprised 97 IBS plus FMS adult females, of whom 58 had LE (Marsh stage 1), and 39 had a normal duodenal biopsy (Marsh stage 0). All patients fulfilled the Rome III and American College of Rheumatology 1990 criteria. All participants followed a GFD, the effectiveness of which was assessed by changes in the results of several tests, including those of the Fibromyalgia Impact Questionnaire (FIQ), the Health Assessment Questionnaire (HAQ), tender points (TPs), the Short Form Health Survey (SF-36), and the Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and fatigue. RESULTS: At baseline, all patients had a poor quality of life (QoL) and high VAS scores. After one year on a GFD, all outcome measures were somewhat better in the Marsh stage 1 group, with a mean decrease of 26 to 29% in the TPs, FIQ, HAQ and VAS scales, accompanied by an increase of 27% in the SF-36 physical and mental component scores. However, in the IBS plus FMS/Marsh stage 0 group, the GFD had almost no effect. CONCLUSIONS: This pilot study shows that a GFD in the LE-related IBS/FMS subgroup of patients can produce a slight but significant improvement in all symptoms. Our findings suggest that further studies of this subject are warranted.